Canadian Journal of Gastroenterology and Hepatology / 2018 / Article / Tab 2

Research Article

Glucose Metabolism Changes in Patients with Chronic Hepatitis C Treated with Direct Acting Antivirals

Table 2

Baseline laboratory parameters and DAA treatment parameters by degree of fibrosis.

F0-F2 
N=118 
Absolute (relative) 
counts or mean ± SEM
F3 
N=80 
Absolute (relative) 
counts or mean ± SEM
F4 
N=170 
Absolute (relative) 
counts or mean ± SEM
P

HCV RNA IU/mL2 945 961±640 6442 428 590±429 2972 799 155±348 2750.427 K-W test

Treatment

 3D combo83 (70.3)43 (53.8)96 (57.8)<0.0001
 SOF LDV21 (17.8)35 (43.8)64 (38.6)
 other14 (11.9)2 (2.5)6 (3.6)

Ribavirin19 (16.2)18 (22.8)106 (63.9)<0.0001

Treatment duration

 <8 weeks (incomplete)4 (3.4)1 (1.3)4 (2.4)0.611
 8 weeks2 (1.7)00
 12 weeks109 (93.2)76 (95)155 (93.4)
 24 weeks2 (1.7)3 (3.8)7 (4.2)

SVR89 (96.7)74 (97.4)144 (96.0)0.862

Creatinine umol/L (n=366)139.5±17.584.2±6.279.9±5.8<0.0001

CRP mg/dL (n=127)3.5±0.784.3±1.601.6±0.190.012

Hb g/L (n=368)142±1.7144±2138±1.40.023

Neutrophils 109/L (n=258)4.01±0.183.32±0.172.8±013<0.0001

Platelets 109/L (n=368)206±6.9200±7.5132±5<0.0001

AFP kIU/L (n=240)5.4±0.97.6±0.622.3±0.2<0.0001

Albumin g/L (n=354)41.6±0.441.5±0.438.6±0.4<0.0001

INR (n=335)1.02±0.021.05±0.031.13±0.01<0.0001

AST %ULN (n=281)133.6±14.5145.6±10.0234.3±14.9<0.0001

ALT %ULN (n=368)175.40±14.2166.2±10.8229.5±13.90.002

GMT %ULN (n=281)154.6±15.6144.3±14.4241.5±30.40.01

ALP %ULN (n=281)76.7±4.169.1±2.992.9±4.1<0.0001

Bilirubin umol/L (n=368)12.9±1.013.2±0.519.7±1.0<0.0001

Conj. Bil. umol/L (n=184)5.4±1.63.6±0.38.5±1.030.01

Glucose (mmol/l)5.75±0.185.84±0.176.69±0.20.001

Total cholesterol (mmol/L) n=3284.45±0.104.69±0.104.19±0.080.001

HDL-C (mmol/L) n=1401.34±0.051.32±0.071.27±0.060.622

LDL-C (mmol/L) n=1362.73±0.122.48±0.152.33±0.090.02

Triglycerides (mmol/L) n=2011.37±0.081.27±0.101.54±0.090.165

AIP n=140-0.03±0.03-0.03±0.050.04±0.040.272

FORNS5.74±0.236.18±0.238.19±0.18<0.0001

FIB-41.8±0.152.55±0.275.77±0.54<0.0001

APRI0.76±0.090.9±0.12.27±0.18<0.0001

TELP (kPa)6.14±0.237.61±0.4720.07±1.27<0.0001

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.